Healthspan vs. Lifespan. Why Living Longer Means Nothing Without This.
Modern medicine has become extraordinarily good at keeping people alive. The question it has been slower to answer is what quality of life looks like across those added years. The science of healthspan is changing that conversation entirely.
In 1900, the average life expectancy in the United States was 47 years. Today it is approaching 79. That is an extraordinary achievement of public health, sanitation, medicine, and nutrition science. In roughly a century, we added three decades to the average human lifespan.
But there is a question embedded in that achievement that medicine has been slower to answer. Not how long are people living, but how well are they living across those additional years. Are those extra decades defined by vitality, strength, cognitive sharpness, and physical independence? Or are they years of managed decline, accumulated medication, progressive frailty, and the gradual erosion of the capacity to do the things that make life worth living?
The answer, for a significant portion of the population, is closer to the second description than anyone working in longevity science is comfortable with. And it has given rise to one of the most important distinctions in modern biology: the difference between lifespan and healthspan.
How Long You Live
The total number of years from birth to death. Modern medicine has extended lifespan significantly through disease management, surgical intervention, and pharmaceutical support.
How Well You Live
The number of years lived in full physiological function, free from chronic disease, disability, and significant decline. Healthspan optimization is the frontier where the most consequential longevity science is happening now.
The gap between lifespan and healthspan in the average adult is currently estimated at approximately ten years. That is a decade spent in meaningful functional decline before death. Ten years of reduced independence, accumulated chronic conditions, and the progressive loss of physical and cognitive capacity. The goal of healthspan science is to compress that gap, to extend the period of full function and push the period of decline as late as possible, as briefly as possible.
Understanding what drives that gap, at the cellular and molecular level, is where the science becomes both humbling and genuinely hopeful.
The Hallmarks of Biological Aging
In 2013, a landmark paper published in the journal Cell by Lopez-Otin and colleagues identified nine hallmarks of biological aging: the cellular and molecular processes that drive the functional decline associated with getting older. That framework has since been updated to include twelve hallmarks, and it represents the current scientific consensus on what aging actually is at the level of biology.
Understanding these hallmarks matters because they are not abstract. Several of them are directly addressable through lifestyle, nutrition, and targeted supplementation. The science of healthspan is, in large part, the science of slowing, reversing, or working around these processes.
Accumulated DNA damage from environmental exposures, metabolic byproducts, and replication errors. NAD+-dependent repair enzymes are the primary cellular defense against this damage.
Progressive shortening of the protective caps on chromosomes with each cell division. Shorter telomeres are associated with accelerated biological aging and higher disease risk.
Changes in gene expression patterns that accumulate with age and drive many of the functional declines associated with getting older. Epigenetic clocks can now measure biological age independently of chronological age.
Declining ability to maintain protein quality control. Misfolded proteins accumulate and impair cellular function, contributing to neurodegenerative disease and metabolic decline.
Age-related dysfunction in the cellular pathways that sense and respond to nutrient availability, including mTOR, AMPK, and insulin signaling. Directly relevant to anabolic resistance and metabolic decline.
Progressive decline in mitochondrial number, efficiency, and quality. The primary driver of the cellular energy loss that underlies fatigue, muscle weakness, and cognitive decline in aging adults.
Accumulation of cells that have stopped dividing but resist death, releasing inflammatory compounds that damage surrounding tissue. A key driver of the chronic low-grade inflammation associated with aging.
Declining capacity of tissue stem cell populations to regenerate and repair. Directly related to slower wound healing, reduced muscle regeneration, and impaired immune function with age.
Age-related changes in the signaling molecules cells use to communicate, including inflammatory cytokines, hormones, and growth factors. Drives the systemic inflammation and hormonal dysregulation of midlife.
Of these nine hallmarks, mitochondrial dysfunction and the NAD+ decline that drives it are among the most clinically relevant for adults in midlife, because they sit upstream of so many of the other processes. When cellular energy production fails, everything that depends on it fails with it.
NAD+ and the Energy Crisis of Aging
NAD+, or nicotinamide adenine dinucleotide, is a coenzyme found in every cell in the human body. It serves two primary functions that are directly relevant to the biology of aging. First, it is an essential substrate for cellular energy production through the mitochondrial electron transport chain. Second, it activates a class of proteins called sirtuins, which regulate DNA repair, inflammatory response, circadian rhythm, and biological aging rate.
NAD+ levels decline by approximately 50 percent between the ages of 40 and 60 in most adults. That decline is not a peripheral effect of aging. It is one of its primary drivers.
A 2013 study in Cell by Gomes and colleagues demonstrated that NAD+ decline in aging mice was the upstream cause of mitochondrial dysfunction, and that restoring NAD+ levels through NMN supplementation reversed the mitochondrial aging phenotype within one week. The authors described the finding as comparable to a 60-year-old having the mitochondrial function of a 20-year-old after treatment.
A 2018 human clinical trial published in Nature Communications confirmed that nicotinamide riboside (NR) supplementation safely and significantly elevated NAD+ levels in healthy middle-aged and older adults within two weeks, with sustained elevation over the 12-week study period. No significant adverse effects were observed.
Research from the Sinclair Lab at Harvard has established that NAD+ decline is one of the most well-supported upstream drivers of the epigenetic aging process, and that interventions that restore NAD+ availability consistently produce measurable improvements in multiple hallmarks of biological aging simultaneously.
The mechanism matters here. NAD+ does not just provide energy. It activates SIRT1 and SIRT3, two of the most studied sirtuin proteins, which in turn regulate mitochondrial biogenesis, the creation of new mitochondria to replace aging ones. When NAD+ is sufficient, the cell can maintain its mitochondrial population, repair DNA damage efficiently, and regulate the inflammatory pathways that drive chronic low-grade inflammation. When NAD+ is depleted, these processes slow, stall, and in some cases reverse.
This is why NR at a clinical 350mg dose is not a peripheral ingredient in a longevity-focused formula. It is addressing one of the most fundamental upstream drivers of biological aging currently identified in the research literature.
Epigenetic Age and What You Can Actually Change
Chronological age is the number of years since you were born. Biological age is the age your cells and tissues appear to be based on their molecular state. These two numbers are not always the same, and the gap between them is one of the most revealing measures in longevity science.
Epigenetic clocks, pioneered by researchers including Steve Horvath at UCLA, measure biological age by analyzing DNA methylation patterns, chemical modifications to DNA that change predictably with age and accumulate in response to lifestyle, stress, nutrition, and environmental exposures. A person with a biological age ten years older than their chronological age is carrying the cellular burden of a decade of additional aging. A person with a biological age ten years younger is operating with a meaningful physiological advantage regardless of what their birth certificate says.
A 2023 study published in Aging Cell found that a combination of lifestyle interventions including resistance training, dietary protein optimization, stress management, and targeted supplementation produced measurable reductions in epigenetic age over an eight-week period in adults over 50, with the average participant reducing their biological age by over three years.
Research from the Blackburn Lab at UCSF demonstrated that lifestyle factors including exercise, diet quality, sleep, and stress management are among the strongest known modifiers of biological aging rate, with the effect sizes comparable to or exceeding those of most pharmaceutical interventions studied to date.
A 2021 review in Nature Reviews Molecular Cell Biology confirmed that epigenetic aging is not a fixed trajectory. It is a dynamic process that responds to environmental inputs, with several lifestyle and nutritional interventions now demonstrating statistically significant effects on biological age biomarkers in human clinical studies.
The practical implication is significant. Biological age is not destiny. It is a current measurement of a dynamic process. And that process responds to inputs that are available to anyone willing to take them seriously.
Biological age and chronological age are not the same number. The gap between them is one of the most important metrics in longevity science and one of the most actionable.
Mitochondrial Health and the Energy of Longevity
Mitochondria are the organelles responsible for producing the ATP that powers virtually every energy-demanding process in the body. A healthy adult cell contains between 1,000 and 2,500 mitochondria. Their efficiency, number, and quality decline measurably with age, and that decline is directly responsible for the fatigue, reduced exercise capacity, slower recovery, and cognitive changes that most adults over 50 experience.
Mitochondrial biogenesis, the process of creating new mitochondria to maintain population quality, is driven primarily by a protein called PGC-1 alpha. PGC-1 alpha is activated by two primary inputs: exercise, specifically the cellular energy stress of resistance and aerobic training, and NAD+ availability through the sirtuin pathway. Both inputs are required. Neither alone is sufficient for optimal mitochondrial health in an aging body.
Mitochondrial decline is one of the primary reasons training results diminish with age even when effort does not. Fewer, less efficient mitochondria mean less ATP available for muscle contraction, slower recovery between sets, reduced capacity for the volume of work that produces adaptation, and longer recovery time between sessions.
Supporting mitochondrial biogenesis through both the training stimulus and the NAD+ pathway is not a fine-tuning strategy for advanced athletes. It is a foundational requirement for any adult over 40 who wants their training to produce results proportional to their effort.
Pterostilbene and the Sirtuin Amplifier
Pterostilbene is a polyphenol found in blueberries and grapes, structurally similar to resveratrol but with significantly superior bioavailability. Where resveratrol has a bioavailability of roughly 20 percent, pterostilbene reaches approximately 80 percent, making it far more effective at achieving meaningful tissue concentrations from oral supplementation.
Pterostilbene activates SIRT1, the same sirtuin pathway stimulated by NAD+, through a complementary mechanism. When pterostilbene and NR are combined, their effects on the sirtuin pathway are additive. Both compounds support the same longevity-relevant biological processes through different molecular entry points, making them a well-supported combination in longevity-focused formulations.
A 2012 study in Agricultural and Food Chemistry confirmed that pterostilbene demonstrates superior bioavailability and tissue retention compared to resveratrol, with a half-life approximately four times longer, allowing for more sustained biological activity from standard oral doses.
Research published in Oxidative Medicine and Cellular Longevity found that pterostilbene supplementation significantly reduced markers of oxidative stress and inflammation in aging animal models, with effects on multiple hallmarks of biological aging including mitochondrial function, DNA damage response, and inflammatory cytokine production.
A 2014 human clinical trial found that pterostilbene at doses consistent with supplementation produced statistically significant reductions in blood pressure and LDL cholesterol, with a favorable safety profile across the study period.
This is why Silbinol® pterostilbene at 100mg is in MYO Daily. Not as a token antioxidant addition. As a specific activator of the sirtuin and mitochondrial pathways that the NAD+ component is also targeting, chosen for its bioavailability profile and its complementary mechanism of action.
What Muscle Has to Do With All of This
Skeletal muscle is not peripheral to the science of healthspan. It is central to it. Muscle tissue is the largest site of mitochondrial density in the body. It is the primary site of glucose disposal and insulin signaling. It produces myokines that communicate directly with the brain, liver, immune system, and adipose tissue. And muscle mass is one of the strongest independent predictors of healthspan outcomes available in the longitudinal data.
A 2014 study in the American Journal of Medicine found that muscle mass index was a stronger predictor of all-cause mortality than either BMI or body fat percentage. Every unit of muscle mass lost to sarcopenia represents a reduction in metabolic reserve, immune capacity, and physiological resilience that compounds over time. Preserving and building muscle after 40 is not an aesthetic goal. It is one of the highest-leverage healthspan interventions available without a prescription.
This is where the MYOCODE system connects the cellular and the structural. MYO Daily addresses the upstream biology: NAD+ restoration, mitochondrial support, sirtuin activation, and metabolic health. MYOCODE Protein addresses the downstream structure: clinical protein dosing, leucine threshold delivery, and the substrate your muscle tissue needs to respond to the training stimulus. Together they are addressing healthspan from both directions simultaneously.
The Bottom Line
The science of longevity has moved well beyond the question of how long people can live. The frontier is how well, and the research is increasingly clear about what the levers are. NAD+ restoration addresses one of the most well-documented upstream drivers of biological aging. Mitochondrial support addresses the energy system that every other cellular process depends on. Muscle preservation addresses the structural organ most predictive of long-term functional health. And epigenetic evidence confirms that biological aging is not a fixed trajectory. It responds to the right inputs.
Living longer is not the goal on its own. Living well across every decade you have is the goal. And the science to support that, taken seriously and applied consistently, is more powerful than the standard aging narrative has ever acknowledged.
The gap between lifespan and healthspan is not inevitable. It is a measurement of inputs. Change the inputs, and the measurement changes with them.
Cellular longevity support built on the science.
MYO Daily combines 350mg NR for NAD+ restoration, 100mg Silbinol® pterostilbene for sirtuin activation, 5g creatine for cellular energy and muscle support, and 3g myHMB® for muscle preservation — formulated specifically around the upstream biology of healthspan.
Shop MYO Daily- Lopez-Otin C, et al. "The hallmarks of aging." Cell. 2013;153(6):1194–1217.
- Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638.
- Martens CR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications. 2018;9(1):1286.
- Horvath S. "DNA methylation age of human tissues and cell types." Genome Biology. 2013;14(10):R115.
- Fitzgerald KN, et al. "Potential reversal of epigenetic age using a diet and lifestyle intervention." Aging. 2021;13(7):9419–9432.
- Srikanthan P, Karlamangla AS. "Muscle mass index as a predictor of longevity in older adults." American Journal of Medicine. 2014;127(6):547–553.
- Bhullar KS, Hubbard BP. "Lifespan and healthspan extension by resveratrol." Biochimica et Biophysica Acta. 2015;1852(6):1209–1218.
- Kosuru R, et al. "Promising therapeutic potential of pterostilbene and its mechanistic insight based on preclinical evidence." European Journal of Medicinal Chemistry. 2016;115:496–510.
- Riche DM, et al. "Analysis of safety from a human clinical trial with pterostilbene." Journal of Toxicology. 2013;2013:463595.
- Hood DA, et al. "Maintenance of skeletal muscle mitochondria in health, exercise, and aging." Annual Review of Physiology. 2019;81:19–41.